Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 15:1:29.
doi: 10.12688/wellcomeopenres.9964.1.

Effects of tranexamic acid on platelet function and thrombin generation (ETAPlaT): WOMAN trial sub-study

Kastriot Dallaku  1   2 , Haleema Shakur  3 , Ian Roberts  3 , Phil Edwards  3 , Danielle Beaumont  3 , Maria Delius  4 , Braun Siegmund  5 , Orion Gliozheni  2 , Ilir Tasha  2 , Saimir Cenameri  2 , Ulrich Mansmann  1
Affiliations

Effects of tranexamic acid on platelet function and thrombin generation (ETAPlaT): WOMAN trial sub-study

Kastriot Dallaku et al. Wellcome Open Res. .

Abstract

Background. Postpartum haemorrhage (PPH) is a leading cause of maternal death. Tranexamic acid (TXA) has the potential to reduce bleeding and a large randomized placebo controlled trial of its effect in women with PPH (The WOMAN trial) is underway. TXA might also affect coagulation factors and platelets. Objectives. To examine the effect of TXA on thrombin generation, platelet function, fibrinogen, D-dimer and coagulation factors in women with PPH. Methods. We will conduct a sub-study within the WOMAN trial. Women with clinically diagnosed primary PPH after vaginal or caesarean delivery are eligible for inclusion. Blood samples will be collected at baseline and 30 minutes after the first dose of study treatment. Using platelet poor plasma we will measure thrombin generation, fibrinogen, D-dimer, factor V and VIII, and Von Willebrand factor. Platelet function will be evaluated in whole blood using Multiplate® tests. Outcomes. The primary outcome is the effect of TXA on thrombin generation. Secondary outcomes include the effect of TXA on platelet function, fibrinogen, D-dimer and coagulation factors.

Keywords: Coagulation Factors; Platelet function; Postpartum Hemorrhage; Tranexamic Acid.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. Algorithm of the WOMAN-ETAPlaTsub-study.
Black boxes: Standard procedure of the WOMAN trial. Red boxes: Additional procedures required for the ETAPlaT sub-study.
See this image and copyright information in PMC

References

    1. Boylan JF, Klinck JR, Sandler AN, et al. : Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology. 1996;85(5):1043–8. - PubMed
    1. Ervin AL, Peerschke EI: Platelet activation by sustained exposure to low-dose plasmin. Blood Coagul Fibrinolysis. 2001;12(6):415– 425. 10.1097/00001721-200109000-00001 - DOI - PubMed
    1. Godier A, Roberts I, Hunt BJ: Tranexamic acid: less bleeding and less thrombosis? Crit Care. 2012;16(3):135. 10.1186/cc11374 - DOI - PMC - PubMed
    1. Hedner U: Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost. 2008;100(4):557–62. 10.1160/TH08-07-0434 - DOI - PubMed
    1. Mezzano D, Panes O, Muñoz B, et al. : Tranexamic acid inhibits fibrinolysis, shortens the bleeding time and improves platelet function in patients with chronic renal failure. Thromb Haemost. 1999;82(4):1250–4. - PubMed

LinkOut - more resources